The authors of the abstract are
"It is now evident to everyone that we have taken the first step towards building a health economical file for NEX-20 for the treatment of multiple myeloma", says
© Modular Finance, source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.88 SEK | +4.76% | +18.92% | -28.46% |
05-03 | Nanexa AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-16 | Nanexa AB Announces Approval of Clinical Trial Application for NEX-22 Study Delayed | CI |
The authors of the abstract are
"It is now evident to everyone that we have taken the first step towards building a health economical file for NEX-20 for the treatment of multiple myeloma", says
© Modular Finance, source
1st Jan change | Capi. | |
---|---|---|
-28.46% | 10.52M | |
-5.44% | 192M |